The MSA Is the Cap Table: How to Read a Legal MSO Like a Bond Indenture

Two valuation shops. Two sentences. The same document.

VMG Health, after reviewing more than 120 management services agreements in healthcare, the industry where this structure grew up, calls demonstrating that the management fee is subordinated to most other expenses and fees "imperative." L.E.K. Consulting, describing legal MSOs: "the MSO fee is paid before partner distributions."

Same document name. Inverted waterfall. In medicine, the management company waits at the back of the line, behind the expenses that pay the physicians. In law, the investor's fee is paid first.

A fixed claim, paid first, on someone else's enterprise has a name in finance, and the name is not equity. It is a bond. And which bond you hold does not live in the revenue line. It lives in four clauses · exclusivity, expansion rights, IP ownership, fee seniority. The rest of this memo is how to rate them.

The waterfall runs backwards

Start with what the healthcare data actually shows, because healthcare is where every legal-MSO playbook claims its pedigree. VMG Health studied more than 120 management services agreements in healthcare deals and concluded that subordinating the management fee is "imperative" for a defensible arrangement. Only about 10 percent of the agreements in its sample lacked priority-of-payment language or carried a waterfall that failed to subordinate the fee. Nearly half, 47 percent, went further in the other direction: deficit-loan-funding covenants that put the MSO's own capital at risk when the practice runs short. Two decades of regulatory pressure taught healthcare investors to stand at the back of the line. (VMG's exact formulation is "most other expenses and fees" rather than "physician compensation" by name; the inversion we are about to draw is our reading of the two waterfalls set side by side.)

Now the legal version. L.E.K., in its published guidance on how investors evaluate legal MSO opportunities, states the seniority plainly: "Since the MSO fee is paid before partner distributions, successful deals build alignment through fair market value fees, scope adjustment terms and rollover equity." Paid before partner distributions. The management fee that healthcare practice forces to the back of the waterfall sits at the front of the waterfall in law.

Here is the strange part. Sophisticated investors already underwrite the MSA hard. L.E.K. publishes diligence screens for it. Every serious buyer treats the management services agreement as the foundation of the deal. The document is on the list. But it is underwritten as equity diligence · a durability check on a growth position. Will the contract hold, will the revenue persist, does the platform scale. Right document, wrong discipline.

Because if the fee is senior, the next question is not whether the contract is durable. The next question is what the so-called equity actually owns.

Rule 5.4 deletes the equity

ABA Model Rule 5.4 bars nonlawyers from owning an interest in a law firm, bars lawyers from sharing legal fees with nonlawyers, and protects the lawyer's independent professional judgment from outside control. It governs in 48 states, with the Arizona ABS regime and the Utah sandbox as the carve-outs, plus the District of Columbia's narrower allowance for minority nonlawyer partners. Arizona shows what the exception looks like at scale: 151 alternative business structures licensed by the Arizona Supreme Court as of January 2026, with estimates suggesting private equity and hedge funds back somewhere near half of them. Everywhere else, the rule holds, and the deal literature treats it as the great friction of legal-services investing.

Read it instead as a security-design constraint, because that is what it functionally is. Walk through what an equity claim on an enterprise normally confers and watch Rule 5.4 delete each one. A share of profits? Deleted: no percentage of legal fees, gross or net, ever. Control? Deleted: no vote over hiring, strategy, settlement, or any exercise of professional judgment. The residual claim, the right to whatever value is left after every fixed obligation is paid? Deleted: nonlawyers cannot hold the residual interest in a law firm at all. Sidley's two never-cross lines, fair-market fees and no control of professional judgment, are simply this deletion stated as compliance guidance.

What survives the deletion is exactly one ownable economic object: a contract. The investor's capital buys equity in the MSO, true, but look through the MSO to its claim on the law firm and you find no shares, no votes, no residual · only the management services agreement, a negotiated schedule of cash flows with a stated term, a stated priority, and stated conditions of default. The equity investor in a legal MSO is, economically, a creditor of the law firm.

A fixed contractual claim on another enterprise's cash flows, with negotiated priority, duration, and default triggers, has a mature literature. It is called fixed income, and its governing document is called an indenture.

Read the MSA like an indenture

Every diligence question a fund knows how to ask about a legal MSO has a sharper fixed-income twin. Term is duration: how long does this claim pay before it must be re-won? Fee seniority is coupon priority: where does the payment sit in the waterfall, and does the contract say so or merely assume so? Termination rights are events of default: under what conditions does the claim accelerate, cure, or die? Renewal is refinancing: on what terms does the issuer roll the obligation, and who holds the leverage at that moment?

This is not a metaphor we are imposing on the market. Half the market already reads the document this way · the half that lends. Holland & Knight, writing on MSO acquisition financing in November 2025, reports that "MSO lenders primarily underwrite the stability of the management relationship and the predictability of MSA revenue," and that lenders scrutinize the term, renewal, termination, and assignment provisions of the MSA along with the fee-calculation methodology. Sidley, in the second installment of its series on private equity investment in US law firms, calls the MSA "the fulcrum of the MSO structure" and the "economic backbone of the investment transaction," and notes that lenders commonly require security interests in, and collateral assignments of, the management services agreement itself.

Both firms are right, and both stop one step short. They treat the MSA as collateral · the thing that secures the debt. Our claim is one notch stronger: for the equity, the MSA is the security. Not the safeguard of the instrument. The instrument. There is no enterprise value standing behind it that the investor may reach by other means; Rule 5.4 burned the other means. The lender market reads the indenture because lenders always read indentures. The equity market, meanwhile, runs growth-equity analysis on what is economically a credit instrument, and the toolkit misprices everything it touches: revenue multiples size a coupon, growth narratives describe someone else's enterprise, and management premium prices a team that cannot legally own the upside it is being priced for.

One feature of this instrument has no precedent anywhere in fixed income. A bondholder takes the indenture the issuer offers, negotiated at the margin through underwriters. The MSO sponsor drafts the MSA before the structure exists. The covenants, the priority language, the term, the default triggers, the expansion rights: the buyer writes all of it, then funds against it. It is the only bond whose buyer writes the indenture. That is an extraordinary privilege, and the discipline it demands is the subject of the next two sections.

One disclaimer, placed here at the metaphor's birth, because precision matters more than rhetoric: this is an analytic lens for valuation discipline, not a claim that a management services agreement is a security, a bond, or any other regulated instrument in a statutory sense. Nothing in this memo is legal or investment advice.

Two MSOs, identical revenue, different asset classes

Consider a hypothetical pair, MSO A and MSO B, offered here purely as an illustration and not describing any actual company or agreement. Each collects $20 million a year in management fees from its affiliated firm. On a deck, they are the same deal. Read as indentures, they are not even the same asset class.

MSO A holds the exclusive right to provide its full service scope to the firm, nationwide. Its MSA embeds expansion rights: new practice lines, new geographies, and successor or affiliated firms come to the MSO on pre-agreed terms, not through fresh negotiation. It owns the brand and the technology, data, and analytics platforms outright and licenses them to the firm. Its fee sits behind an express priority-of-payment clause, senior to all partner distributions.

MSO B is non-exclusive; the firm may self-provide or dual-source any function it likes. Its scope is static; every new service line is a new negotiation from a standing start. It licenses the brand back from the partners, who kept it. And its agreement contains no waterfall language at all; the fee's seniority is implied by practice and nothing else, the legal transposition of the 10 percent of healthcare MSAs VMG flagged as missing priority-of-payment terms.

Same coupon. Different instruments. A's revenue is a senior claim wrapped in options on the firm's growth; B's is an unsecured, junior-in-practice service relationship that the obligor can hollow out without breaching anything. Note also which of the four terms the MSO literature has never even named: exclusivity, IP ownership, and fee structure all appear in the law-firm advisories; expansion rights, the clause that determines whether the claim can grow without renegotiation, appears in none of them. There is a darker variant of B circulating as well. Law360, reporting on the private equity move into legal services, describes arrangements in which the parties "try to draft more creative terms that allow the service organization to share in the success of the firm" while, in its telling, staying on the right side of fee-sharing rules. Those terms are not upside. They are drift toward the fee-sharing line, and the rubric below scores them where they belong.

The market has begun producing real reference points. In April 2026, an Arizona personal-injury firm announced a roughly $125 million minority investment through its management company, Rafi Law Services, with about 250 staff moving to the MSO and the firm's 26 attorneys staying behind, per Bloomberg Law (April 6, 2026); the firm's own announcement put the implied valuation of the MSO near $450 million. We take no view on that transaction. We simply observe what the headline cannot tell you: the revenue is public, the valuation is public, and the four terms are not. Which tier the deal's MSA actually occupies is precisely the question the press release does not answer, and precisely the question the price depends on.

Tiering demands a rating, not adjectives.

The rating rubric

L.E.K.'s published diligence criteria are the closest prior framework, and they deserve to be named: fair-market fees, scope adjustment, alignment mechanics, MSA durability. What they lack is what turns screens into a rating · tiers, an explicit aggregation rule, and the four terms themselves. Below is the rubric. A note on its architecture: it has six rows but the coinage names four terms, by design. Duration and termination are the indenture frame every MSA shares; they set the instrument's life and its events of default. The four differentiators · exclusivity, expansion rights, IP ownership, fee seniority · decide which asset class you hold within that frame. The frame is the bond. The four terms are the cap table.

Aggregation rule. Score each row to a tier off its contract-language markers. The composite rating is the lowest tier among the four differentiator rows · a weakest-covenant rule, because credit breaks at the weakest link and so do MSAs. The two frame rows can never raise a rating, but a Junk score on either caps the composite at Speculative. Notches: one notch down for regulatory exposure in an enacted-statute state (the HB 5487 class, on which more below), and one notch down for deficit-loan-funding covenants of the kind VMG found in 47 percent of healthcare MSAs. Notches move within a tier; two accumulated notches drop the composite one full tier.

Applied. The footer row scores the worked pair. Identical $20 million revenue. Two tiers apart. That distance is invisible to a revenue multiple and obvious to a credit analyst, which is the entire point.

The capped coupon objection

The sophisticated reader has been objecting for three sections, so let the objection arrive at full strength. You have described an instrument with the downside of credit and none of its protections, plus the upside of nothing. The fee is capped at fair market value; Texas Ethics Opinion 706 holds flatly that "a lawyer may not agree to pay a nonlawyer-owned vendor based on a percentage of the revenues of the lawyer or the lawyer's firm," so there is no torque in the coupon. The claim is structurally senior but legally unsecured and terminable. Regulation is a live tail risk no covenant cures. If the equity is really a capped bond, the rational move is to be the lender: cheaper entry, true security, the same cash flows. The lens, taken seriously, kills the asset class it was built to rate.

Take the pieces in order.

The cap binds the fee rate, not the claim's value. Texas Op. 706 and its analogues prohibit one thing: percentage participation in legal fees. They say nothing about the value levers that live elsewhere in the indenture, all of them lawful and all of them uncapped. Duration can extend. Renewal can reprice, at fair market value, against a cost base and a service scope the MSO has spent the term improving. Expansion rights convert the firm's growth into new contracted scope without touching its fees. Exclusivity breadth determines how much of the firm's operating spend the claim addresses at all. Each of these is, in fixed-income terms, an embedded call option on the growth of the obligor · and the holder drafted every one of them personally. The instrument is not a capped bond. It is a senior credit with a strip of warrants the buyer wrote into the indenture.

The be-the-lender move fails for the same reason. A lender gets the coupon and the collateral assignment; Holland & Knight's lender checklist is real, and it is also the ceiling of the lender's position. The lender does not hold the expansion rights, does not own the brand and the platforms, does not reprice at renewal, and does not write the covenants · the MSO sponsor does all four. And there is an equity kicker the lender never touches: at exit, operating platforms in adjacent consolidations have historically commanded a premium over single-asset positions, a pattern we note as contested and leave at one sentence.

The regulatory tail is real, and the honest response is to price it, not argue with it. Illinois HB 5487, passed on May 31, 2026 and awaiting the governor's signature as of early June 2026, would prohibit MSO fees "directly or indirectly based on a lawyer's or law firm's fees, revenues or profits," ban post-termination noncompetes, and bar nonlawyer interference with professional judgment, for firms under $300 million in revenue. California's AB 931, signed in October 2025, bars California lawyers from sharing fees that scale with recovery with out-of-state alternative business structures with nonlawyer ownership through 2030, while expressly leaving room for flat-fee arrangements that neither pay for referrals nor scale with recovery. Notice what both statutes actually target: percentage fees, success-linked terms, control creep. Which is to say, the Junk column of the rubric. The legislatures are not outlawing the asset class; they are enacting its rating criteria. An investment-grade MSA, on these texts, is the structure that survives. The rubric prices the exposure anyway · that is what the enacted-statute notch is for · because restraint, not confidence, is what the tail deserves.

So the bond reading is not a demotion of the asset. It is the only honest path to its premium. Which is why the last scene belongs at the closing table.

Underwriting the indenture

Picture the table at signing. On one side sits the lender, who has read the management services agreement line by line, because lenders always read the indenture; its credit committee memo quotes the termination section. Next to the lender sits the equity sponsor, who has read the deck; the model is beautiful and the MSA is an exhibit. Across from both sits the law firm, which drafted neither. The party with the junior information position is the one calling itself senior.

That scene, not any framework, is the memo's residue. It compresses to one sentence: in any legal-MSO deal, the first diligence request is not the model. It is "send me the MSA," because the four terms are the cap table. And the familiar red flags of this market · terms drifting toward nonlawyer control, pressure for profit-linked compensation · are not ethics trivia to be cleared by a side memo. They are covenant violations, and the rubric scores them as exactly that.

One clause of the indenture deserves a memo of its own. The fee clause does more than set the coupon's seniority; it decides who captures the economics of an efficiency shock, and the largest efficiency shock in the history of professional services is arriving on schedule. That memo is "The AI Dividend Has an Address," next in this series.

---

This memo is published by Jopese, a legal management services organization operated by HIRO PARTNERS LLC, a Texas limited liability company. It is offered for educational and analytical purposes only. It is not legal, tax, or investment advice, and it is not an offer to sell or a solicitation of an offer to buy any security or service. Jopese is not a law firm and does not provide legal advice or legal services; legal services are delivered by an independent law firm under a separate engagement in which Jopese does not participate. The "bond" and "indenture" framing used throughout is an analytical lens only and is not a characterization of any agreement as a security or other regulated instrument. References to specific funds, firms, transactions, statutes, and regulatory developments are drawn from public sources and are provided as market commentary, not as an endorsement, a recommendation, or a representation of any relationship. The MSO comparisons presented above are hypothetical illustrations and do not describe any actual agreement, including any agreement to which Jopese is a party.